Top Markets
Coin of the day
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Rank in Stocks #33294
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Share Price
$0.4264
Last synced: 2022-09-14
Market Cap
$7.93M
Change (1 day)
-16.44%
Change (1 year)
0.00%
Country
US
Trade Caladrius Biosciences, Inc. (CLBS)

Category

Dividend history for Caladrius Biosciences, Inc. (CLBS)
Caladrius Biosciences, Inc. (stock symbol: CLBS) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Caladrius Biosciences, Inc. (CLBS) from 2026 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
Not enough data for the provided dates.
List of all dividend payments
Year Dividend Change
Not enough data for the provided dates.
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
29.00%
BE